Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
FR0012333284
Thu, 09.01.2025
ABIVAX
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion expected in Q2 2025.
Top-line results for the 8-week induction trial anticipated i [ … ]